Table 1.

Cardiotoxicity at time of FDA approval.

Drug	Approval	Participants	Antibody	Cancer type	Cardiotoxicity - related eventsa
Pembrolizumab	2014	834 patients who had no more than one line of prior systemic therapy and not received ipilimumab	Humanized anti-PD-1 IgG4	Melanoma Non-small cell lung carcinoma Squamous cell carcinoma of head and neck Urothelial carcinoma, Head, neck squamous cell cancer	Various heart diseases; 0–4%*: -Myocarditis (0.5%)-Myocardial infarction (2%)-Pericarditis (2%)-Arrhythmia (4%)-Takotsubo syndrome
Nivolumab	2014	142 patients, stratified by BRAF V600 mutation status, 109 patients with BRAF V600 wild–type melanoma	Human anti-PD-1 IgG4	Classical Hodgkin lymphoma Melanoma Non-small cell lung cancer Renal cell carcinoma Small cell lung cancer Squamous cell carcinoma of head and neck	-Myocarditis(<1%)**-Ventricular arrhythmia (1–10%)-Pericarditis (<1%)
Atezolizumab	2016	Urothelial carcinoma; 310 patients had disease progression during or following a platinum platinum–containing chemotherapy, 32% have PD–L1expression	Humanized anti-PDL-1 IgG1	Non-small cell lung cancer, urothelial carcinoma	- Myocarditis** (<1%)-Myocardial infarction
Durvalumab	2017	Urothelial carcinoma; 182 patients who progressed on platinum–containing chemotherapy	Human anti-PDL-1 IgG1	Non-small cell lung cancer, urothelial carcinoma	Myocarditis < 1%
Avelumab	2017		Human anti-PDL-1 IgG1	Urothelial carcinoma, Merkel cell carcinoma	Myocarditis < 1%
Cemiplimab	2018	Efficacy reported in 250 patients; Phase II Trial	Human anti-PD-1 IgG4	Cutaneous Squamous cell carcinoma	Myocarditis

^aLabel of Food and Drug Administration FDA.

^*Included in the label of Food and Drug Administration (Keynote-087- Keynote-170- Keynote-006).

^**Included in the label of Food and Drug Administration (CHECKMATE-037-clinical trials of OPDIVO administered as a single agent or in combination with ipilimumab and POPLAR trial of atezolizumab).